Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2160-2160
Open Access | Times Cited: 19

Showing 19 citing articles:

Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer
Shili Yao, Lu Sun, Ye Lu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 1
Antibody–Drug Conjugates—Evolution and Perspectives
Adriana Aurelia Chiș, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6969-6969
Open Access | Times Cited: 6
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 6
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics
Arya Bhushan, Preeti Misra
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1224-1235
Closed Access | Times Cited: 5
Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore
Wei Wong, Raymond Ng, Mohamed Ismail Abdul Aziz, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2025)
Closed Access
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
Maximilian Marhold, Marta Vaz Batista, Isabel Blancas, et al.
Future Oncology (2025), pp. 1-9
Open Access
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Giannis Mountzios, Stephanie P.L. Saw, Lizza E.L. Hendriks, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102902-102902
Closed Access
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
Yuying Jiang, Yuance Xu, Junqi He, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
R. Tawfiq, Guilherme Sacchi de Camargo Correia, Shenduo Li, et al.
Current Oncology Reports (2025)
Closed Access
Immunotherapy guided precision medicine in solid tumors
Sanjana Mehrotra, Manu Kupani, Jaismeen Kaur, et al.
Advances in protein chemistry and structural biology (2024), pp. 249-292
Closed Access | Times Cited: 2
Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies
Éric Gabison, Antoine Rousseau, M. Labetoulle, et al.
Progress in Retinal and Eye Research (2024) Vol. 103, pp. 101302-101302
Closed Access | Times Cited: 2
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Xinyi Chen, Shabana Habib, Madalina Alexandru, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3260-3260
Open Access | Times Cited: 2
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis
Silvia Belloni, Paola Tiberio, Rita De Sanctis, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104527-104527
Closed Access | Times Cited: 1
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
Shaun Alexander, Umair Aleem, Timothy W. Jacobs, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3345-3345
Open Access
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1701-1701
Open Access
Exploring immunotherapy with antibody-drug conjugates in solid tumor oncology
Takhellambam Malemnganba, Anurag Kumar Pandey, Amit Mishra, et al.
Advances in protein chemistry and structural biology (2024), pp. 259-286
Closed Access
Ocular toxicities of FDA-approved antibody drug conjugates
Shaurey Vetsa, Stephanie Zhang, Walker Kay, et al.
Cutaneous and Ocular Toxicology (2024), pp. 1-12
Closed Access
Revolución de los conjugados anticuerpo-fármaco en el cáncer, ¿a donde vamos?
Nicolle Wagner-Gutiérrez, Vladmir Cláudio Cordeiro de Lima, H. Freitas, et al.
Medicina (2024) Vol. 46, Iss. 2, pp. 357-363
Open Access
Trastuzumab for Active Targeting in Cancer Therapy
Ana Camila Marques, Paulo Costa, Sérgia Velho, et al.
Springer eBooks (2023), pp. 1-30
Closed Access
Page 1

Scroll to top